5AM Ventures

View the org chart displaying its 25 main executives

Most searched biographies at 5AM Ventures

• Andrew Schwab, Founder and Co-Managing Partner
• Kush Parmar, Co-Managing Partner
• John Diekman, Founding Partner

Popular executive movements at 5AM Ventures

• Michael Calore has joined the company as Partner, Head of Investor Relations  (posted on January 30 2024).

Create your alert
to follow the executive moves at 5AM Ventures.

5AM Ventures has 1,475 competitors including Lloyds Development Capital (United Kingdom (UK)), BlackRock (United States (USA)) and WindRose Health Investors (United States (USA)).

Popular M&A news in Fund

• HMC Capital has acquired StratCap (posted on February 28 2024).
• Thomvest Ventures has just announced a $250 Million fundraising (posted on January 17 2024).
• BlackRock has announced the acquisition of Global Infrastructure Partners  (posted on January 15 2024).

Popular contacts in Fund

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer at Valor Equity Partners
• Mortimer Buckley - Chairman of the Board and Chief Executive Officer (retiring in Dec 2024) at Vanguard
• Sebastian Barrack - Head of Commodities at Citadel

Learn more about the Fund industry >

Press releases by 5AM Ventures

• Skye Bioscience Uplists to The Nasdaq Global Market
• Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia | Enliven Therapeutics
• FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting | Rallybio
• Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors | Enliven Therapeutics
• Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) | Rallybio
• Skye Bioscience Announces $40 Million Private Placement Equity Financing
• NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial - Nodthera
• NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors - Nodthera
• Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) | Dianthus Therapeutics
• Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
• View more press releases Close

Social media about 5AM Ventures

• 5AM Ventures on Wikipedia, Google News & Yahoo Finance
• 5AM Ventures on LinkedIn, Twitter & YouTube

Contact by email its executives including Andrew Schwab

Call 5AM Ventures at +1 415...

View the org chart

Register to receive your alert

Report an error